Peter F. Thall

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

P. Thall, F. Khuri, R. Herbst, 2001, Cancer.

Double epigenetic modulation of high‐dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor‐risk relapsed lymphoma

P. Thall, Y. Oki, E. Shpall, 2016, Cancer.

Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study

P. Thall, J. Wolff, A. Mahajan, 2009, Journal of Neuro-Oncology.

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen‐independent prostate carcinoma

P. Thall, C. Logothetis, L. Pagliaro, 2003, Cancer.

Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission

P. Thall, Z. Estrov, H. Kantarjian, 2002, British journal of haematology.